252 related articles for article (PubMed ID: 33451935)
1. Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?
Drobish JN; Bevill MD; Tracy CR; Sexton SM; Rajput M; Metz CM; Gellhaus PT
Urol Oncol; 2021 Apr; 39(4):235.e1-235.e4. PubMed ID: 33451935
[TBL] [Abstract][Full Text] [Related]
2. Systematic Biopsy Does Not Contribute to Disease Upgrading in Patients Undergoing Targeted Biopsy for PI-RADS 5 Lesions Identified on Magnetic Resonance Imaging in the Course of Active Surveillance for Prostate Cancer.
Arabi A; Deebajah M; Yaguchi G; Pantelic M; Williamson S; Gupta N; Park H; Peabody J; Menon M; Dabaja A; Alanee S
Urology; 2019 Dec; 134():168-172. PubMed ID: 31479660
[TBL] [Abstract][Full Text] [Related]
3. Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naïve Patients and Patients with Prior Biopsies.
Preisser F; Theissen L; Wenzel M; Humke C; Bodelle B; Köllermann J; Kluth L; Banek S; Becker A; Roos F; Chun FK; Mandel P
Eur Urol Focus; 2021 Jan; 7(1):39-46. PubMed ID: 31296485
[TBL] [Abstract][Full Text] [Related]
4. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
Maxeiner A; Kittner B; Blobel C; Wiemer L; Hofbauer SL; Fischer T; Asbach P; Haas M; Penzkofer T; Fuller F; Miller K; Cash H
BJU Int; 2018 Aug; 122(2):211-218. PubMed ID: 29569320
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
[TBL] [Abstract][Full Text] [Related]
6. Current role of systematic biopsy in diagnosis of clinically significant prostate cancer in primary combined MRI-targeted biopsy: a high-volume single-center study.
Krausewitz P; Fostitsch D; Weiten R; Kluemper N; Stein J; Luetkens J; Kristiansen G; Ellinger J; Ritter M
World J Urol; 2023 Jan; 41(1):19-25. PubMed ID: 36477403
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
[TBL] [Abstract][Full Text] [Related]
8. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
[TBL] [Abstract][Full Text] [Related]
10. Fourteen-Core Systematic Biopsy That Includes Two Anterior Cores in Men With PI-RADS Lesion ≥ 3 is Comparable With Magnetic Resonance Imaging-ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer: A Single-institution Experience.
Sterling J; Smith K; Farber N; Nagaya N; Jang TL; Singer EA; Sadimin E; Kim IY
Clin Genitourin Cancer; 2021 Aug; 19(4):275-279. PubMed ID: 33153920
[TBL] [Abstract][Full Text] [Related]
11. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
12. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
13. Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies.
Maxeiner A; Nest AM; Stephan C; Cash H; Baur ADJ; Fischer T; Kilic E; Piper SK; Nowak CP; Busch J; Miller K; Mang J
Urol Int; 2020; 104(3-4):205-213. PubMed ID: 31801153
[TBL] [Abstract][Full Text] [Related]
14. Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS™ 5 and Prostate Specific Antigen Density Greater than 15.
Tafuri A; Iwata A; Shakir A; Iwata T; Gupta C; Sali A; Sugano D; Mahdi AS; Cacciamani GE; Kaneko M; Cai J; Ukimura O; Duddalwar V; Aron M; Gill IS; Palmer SL; Abreu AL
J Urol; 2021 Aug; 206(2):289-297. PubMed ID: 33818141
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Magnetic Resonance Imaging/Ultrasound-guided Target Biopsy in Detecting Clinically Significant Prostate Cancer.
Kurokawa G; Mori K; Sasaki H; Nakano J; Takahashi Y; Iwatani K; Urabe F; Tsuzuki S; Koike Y; Sato S; Takahashi H; Miki K; Kimura T
Anticancer Res; 2024 Feb; 44(2):679-686. PubMed ID: 38307559
[TBL] [Abstract][Full Text] [Related]
16. The addition of a sagittal image fusion improves the prostate cancer detection in a sensor-based MRI /ultrasound fusion guided targeted biopsy.
Günzel K; Cash H; Buckendahl J; Königbauer M; Asbach P; Haas M; Neymeyer J; Hinz S; Miller K; Kempkensteffen C
BMC Urol; 2017 Jan; 17(1):7. PubMed ID: 28086856
[TBL] [Abstract][Full Text] [Related]
17. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; van Melick HHE; Somford DM
Eur Urol Oncol; 2020 Apr; 3(2):216-223. PubMed ID: 31239236
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
[TBL] [Abstract][Full Text] [Related]
19. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
[TBL] [Abstract][Full Text] [Related]
20. Is it necessary for all patients with suspicious lesions undergo systematic biopsy in the era of MRI-TRUS fusion targeted biopsy?
Lv Z; Wang J; Wang M; Hou H; Song L; Li H; Wang X; Liu M
Int Braz J Urol; 2023; 49(3):359-371. PubMed ID: 37115180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
